a monoclonal antibody for the prevention of severe influenza A illness

Overall, the safety, tolerability, and pharmacokinetic profile of VIR-2482 at doses up to 1,800 mg supported its further investigation as a long ...

The objective of this study was to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of VIR-2482 in healthy adult subjects.

Vir Biotechnology Announces Topline Data from Phase 2 ...

... first Phase 2 outpatient trial to evaluate the role of a monoclonal antibody in the prevention of influenza A illness. The dose-ranging,

Randomized, Placebo-Controlled Trial to Evaluate the Safety and ...

This double-blind, randomized, placebo-controlled, phase 2 study examined the safety and efficacy of VIR-2482 for seasonal influenza A illness prevention in ...

Can a Monoclonal Antibody Prevent Influenza? - NEJM Journal Watch

The monoclonal antibody VIR-2482 — which targets a conserved region in influenza's hemagglutinin protein — did not avert influenza A illness in ...

New antibody-based prevention and treatment options for influenza

Intravenous administered broadly neutralizing human IgG monoclonal antibodies can reduce influenza symptoms and virus loads. •. Engineered antibody-derived ...

Antibodies may aid effort to fight influenza B: study - VUMC News

The findings reported in the journal Immunity support the development of a monoclonal antibody for prevention and treatment of influenza B ...

BARDA and Vir Biotechnology collaborate to advance development

VIR-2482 is an investigational mAb that is intended to be administered as an intramuscular (IM) injection to prevent illness due to Influenza A.

A Randomized, Placebo-Controlled Trial to Evaluate the Safety and ...

... a monoclonal antibody for the prevention of severe influenza A illness. Antimicrob Agents. Chemother 2024; 68:e0127323. 11. Ng S, Nachbagauer R, Balmaseda A ...

Low Dose Pig Anti-Influenza Virus Monoclonal Antibodies Reduce ...

Future clinical studies should take into account the possibility that mAb therapy may be highly effective in preventing severe disease without ...

Evaluation of MEDI8852, an Anti-Influenza A Monoclonal Antibody ...

We evaluated MEDI8852, a human IgG1 monoclonal antibody that binds a highly conserved influenza A hemagglutinin stalk epitope, in outpatients with ...

A Game Changer for Disease Prevention and Treatment

mAbs are molecules produced in a lab to mimic the antibodies produced naturally by the immune system. When used against infectious diseases, ...

Broadly neutralizing antibodies to combat influenza virus infection

The continuous alteration, including antigen drift and shift of the influenza virus poses a significant challenge in preventing influenza infection. Vaccination ...

Antibodies to combat viral infections: development strategies and ...

Monoclonal antibodies (mAbs) are appealing as potential therapeutics and prophylactics for viral infections owing to characteristics such as their high ...

Monoclonal Antibody for the Prevention of Respiratory Syncytial ...

This systematic review and network meta-analysis compares the efficacy and safety of 4 monoclonal antibodies for preventing respiratory ...

New Class of Monoclonal Antibodies against Severe Influenza - PLOS

A recently discovered class of human monoclonal antibodies with the ability to neutralize a broad spectrum of influenza viruses.

a monoclonal antibody for the prevention of severe influenza A illness

VIR-2482 was well tolerated at all doses studied. The overall incidence of AEs was comparable between VIR-2482 (68.8%) and placebo (85.0%).

Antibody-Based Strategies to Prevent and Treat Influenza - Frontiers

More recently, monoclonal antibodies (mAbs) for viral infections have been developed, including licensure of Synagis for prevention of RSV infection. mAbs for ...

Demonstration by European team of a human monoclonal antibody ...

This is not a new idea. The proposal of using convalescent sera from people who have recovered from a novel influenza to treat those with severe ...

Antibody therapies for the prevention and treatment of viral infections

The human mAb CR8020 has broad neutralizing activity against most group 2 viruses, including H3N2 and H7N7, which cause severe human infection.